Autonomix Medical, Inc.’s Dr. Robert Schwartz Discusses What Positive 4-6 Week Follow-Up Data Means from Lead-In Patients in Ongoing Human Clinical Trial
Autonomix Medical (NASDAQ: AMIX) announced positive 4-6 week follow-up data from the first five lead-in patients in their ongoing proof-of-concept human clinical trial. The study evaluates the safety and effectiveness of their transvascular energy delivery system for ablating problematic nerves to reduce pain in pancreatic cancer patients. Dr. Robert Schwartz, Chief Medical Officer, discussed these results in a Virtual Investor 'What This Means' segment.
Autonomix Medical (NASDAQ: AMIX) ha annunciato dati positivi relativi a un follow-up di 4-6 settimane dai primi cinque pazienti coinvolti nel loro attuale trial clinico di prova di concetto. Lo studio valuta la sicurezza e l'efficacia del loro sistema di somministrazione energetica transvascolare per l'ablazione di nervi problematici al fine di ridurre il dolore nei pazienti affetti da cancro al pancreas. Il Dr. Robert Schwartz, Chief Medical Officer, ha discusso questi risultati in un segmento virtuale per investitori intitolato 'Cosa Significa'.
Autonomix Medical (NASDAQ: AMIX) anunció datos positivos de un seguimiento de 4-6 semanas de los primeros cinco pacientes en su ensayo clínico en curso de prueba de concepto. El estudio evalúa la seguridad y eficacia de su sistema de entrega de energía transvascular para la ablación de nervios problemáticos, con el objetivo de reducir el dolor en pacientes con cáncer de páncreas. El Dr. Robert Schwartz, Director Médico, discutió estos resultados en un segmento virtual para inversores titulado 'Qué Significa Esto'.
오토노믹스 메디컬(NASDAQ: AMIX)은 진행 중인 개념 증명 임상 시험의 최초 5명의 선행 환자에 대한 4-6주 후속 데이터를 발표했습니다. 이 연구는 췌장암 환자의 통증을 줄이기 위해 문제 있는 신경을 제거하는 데 있어 그들의 경혈 에너지 전달 시스템의 안전성과 효과를 평가합니다. 로버트 슈워츠 박사, 최고 의료 책임자가 '이것이 의미하는 바'라는 주제로 가상 투자자 세션에서 이 결과에 대해 논의했습니다.
Autonomix Medical (NASDAQ: AMIX) a annoncé des résultats positifs concernant un suivi de 4 à 6 semaines des cinq premiers patients initiaux dans leur essai clinique humain en cours de preuve de concept. L'étude évalue la sécurité et l'efficacité de leur système de délivrance d'énergie transvasculaire pour l'ablation des nerfs problématiques afin de réduire la douleur chez les patients atteints de cancer du pancréas. Le Dr Robert Schwartz, directeur médical, a discuté de ces résultats lors d'un segment virtuel pour investisseurs intitulé 'Ce que cela signifie'.
Autonomix Medical (NASDAQ: AMIX) hat positive Follow-up-Daten von 4-6 Wochen zu den ersten fünf Vorabpatienten in ihrer laufenden Machbarkeitsstudie vorgestellt. Die Studie bewertet die Sicherheit und Wirksamkeit ihres transvaskulären Energiesystems zur Ablation problematischer Nerven zur Schmerzreduktion bei Pankreaskrebspatienten. Dr. Robert Schwartz, Chief Medical Officer, diskutierte diese Ergebnisse in einem virtuellen Investorensegment mit dem Titel 'Was bedeutet das?'.
- Positive initial clinical data from first five lead-in patients
- Successfully progressing through proof-of-concept trial phase
- None.
Insights
The announcement of 4-6 week follow-up data from a small lead-in group of five patients in a proof-of-concept trial, while mentioned as "positive," lacks specific details about efficacy metrics, safety outcomes, or statistical significance. Without quantifiable results or detailed clinical outcomes, this news provides substantive information for investors to evaluate the trial's actual progress or potential market impact.
The format of presenting this information through a video segment, rather than a formal clinical data release, suggests this is more of a marketing communication than a significant clinical milestone. For a microcap company (
Access the Virtual Investor “What This Means” Segment here
THE WOODLANDS, TX, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced that it recently participated in a Virtual Investor “What This Means” segment.
For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed the Company’s recently announced 4-6 week positive follow-up data, from the first five “lead-in” patients in the Company’s ongoing proof-of-concept (PoC) human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain.
The “What This Means” segment can be accessed here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
autonomix@jtcir.com
FAQ
What are the results of Autonomix Medical's (AMIX) 4-6 week follow-up data in October 2024?
What is the purpose of Autonomix Medical's (AMIX) current clinical trial?
How many patients were included in AMIX's initial follow-up data analysis?
